Answers are grounded in this paper and cite their sources.
A four-dose course of rituximab partially preserved beta-cell function over a period of 1 year in patients with type 1 diabetes. The finding that B lymphocytes contribute to the pathogenesis of type 1 diabetes may open a new pathway for exploration in the treatment of patients with this condition. (ClinicalTrials.gov number, NCT00279305.)
No takes yet. Share an insight, caveat, or question.
Pescovitz et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: